NEW YORK (GenomeWeb News) – Evotec and the Jain Foundation today said they have extended and expanded their 2012 research collaboration aimed at dysferlinopathy.
Terms of the expanded deal were not disclosed.
Evotec and Jain started a research project in 2012 to develop a cell-based high-throughput screening assay using dysferlin-deficient cells with the goal of identifying compounds that can improve the well-being of dysferlin-deficient muscle cells.
Mutations in or the absence of dysferlin, a protein produced by the dysferlin gene, cause types of muscular dystrophy called limb-girdle muscular dystrophy type 2B and Miyoshi Myopathy.
"This collaboration highlights both the increasing role that foundations play in delivering solutions for unmet medical needs and also how Evotec's broad and comprehensive discovery platform can be leveraged in support of these goals in a highly efficient and effective manner," Mario Polywka, COO of Evotec, said in a statement.